Prof Anthony Joshua
Biography
Dr Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto, Canada to complete a PhD under the supervision of Dr Jeremy Squire in prostatic carcinogenesis, and a clinical Fellowship under Dr Ian Tannock.
He joined the Department of Medical Oncology at Princess Margaret Cancer Centre in Toronto as a staff oncologist in late 2008, specialising in genito-urinary malignancy and melanoma with research interests in circulating tumour DNA, tumour heterogeneity, mechanisms of enzalutamide resistance and autophagy.
He returned to Australia, joining the Kinghorn Cancer Centre and the Garvan Institute of Medical Research in late 2015. He is currently a conjoint Associate Professor with the University of New South Wales.
Contact Details
- Phone – 02 9355 5655
- Fax – 02 9355 5602
- Admin – jyoti.parmar@svha.org.au
Dr Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto, Canada to complete a PhD under the supervision of Dr Jeremy Squire in prostatic carcinogenesis, and a clinical Fellowship under Dr Ian Tannock.
He joined the Department of Medical Oncology at Princess Margaret Cancer Centre in Toronto as a staff oncologist in late 2008, specialising in genito-urinary malignancy and melanoma with research interests in circulating tumour DNA, tumour heterogeneity, mechanisms of enzalutamide resistance and autophagy.
He returned to Australia, joining the Kinghorn Cancer Centre and the Garvan Institute of Medical Research in late 2015. He is currently a conjoint Associate Professor with the University of New South Wales.
Contact Details
- Phone – 02 9355 5655
- Fax – 02 9355 5602
- Admin – jyoti.parmar@svha.org.au
Education
1997 - MBBS (Hons), University of New South Wales, Sydney - Australia
1995 - BSc, Prince of Wales Hospital, Sydney - Australia
Selected Publications
Niraula S, Templeton AJ, Vera-Badillo FE, Joshua AM, Sridhar SS, Cheung PW, Yip PM, Dodd A, Nugent Z, Tannock IF. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer. Prostate. 2016 Feb 1;76(2):235-42. Coauthor or Collaborator.
Leibowitz-Amit R, Pintilie M, Khoja L, Azad AA, Berger R, Laird AD, Aftab DT, Chi KN, Joshua AM. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. J Transl Med. 2016 Jan 13;14(1):12. Principal Author.
Singnurkar A, Wang J, Joshua AM, Langer DL, Metser U. 18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study. Clin Nucl Med. 2015 Oct 8.
Khoja L, Butler MO, Chappell MA, Hogg D, Joshua AM. Increased treatment-related toxicity subsequent to an anti-PD-1 agent. Curr Oncol. 2015 Aug 22;22(4):e320-2. Senior Responsible Author.
Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer. 2015 Aug 18;3:36. Senior Responsible Author.
Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015 Aug 1;25(4):342-7. Co-Principal Author.
Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F. Treatment of mCRPC in the AR axis-targeted therapy resistant state. Annals of Oncology. 2015 Jun 22. Coauthor or Collaborator.
Seah JA, Leibowitz-Amit R, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM, Sridhar SS. Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer. 2015 Feb 7. Coauthor or Collaborator.
Seah JA, Leibowitz-Amit R, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM, Sridhar SS. Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2015 Feb 7. Coauthor or Collaborator.
Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Kanga N, Zhang JY, Chen X, Wouters BG, Tannock IF. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br J Cancer. 2015 Feb 3. Impact Factor 4.817. Co-Principal Author.
Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, Ryan CJ. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Castration-Resistant Prostate Cancer Patients Treated with Abiraterone. Clin Cancer Res. 2015 Jan 15. Impact Factor 8.193. Coauthor or Collaborator.
Leibowitz-Amit R, Templeton AJ, Alibhai SM, Knox JJ, Sridhar SS, Tannock IF, Joshua AM. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2015 Jan 1;6(1):23-8. Principal Author.
Jo-An Seah; Raya Leibowitz-Amit; Eshetu G Atenafu; Nimira Alimohamed; Jennifer J Knox; Anthony M Joshua; Srikala S Sridhar. Neutrophil-Lymphocyte Ratio (NLR) and Pathological Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. Clinical GenitoUrinary Cancer. 2015 Jan. In Press. Impact Factor 1.693. Coauthor or Collaborator.
Manusow JS, Khoja L, Pesin N, Joshua AM, Mandelcorn ED. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer. 2014 Dec 1;2(1):41. Senior Responsible Author.
Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate. 2014 Nov 1;74(15):1544-50. Senior Responsible Author.